Multicenter phase II study of neoadjuvant lapatinib and trastuzumab with hormonal therapy and without chemotherapy in patients with human epidermal growth factor receptor 2–overexpressing breast cancer: TBCRC 006

Journal of Clinical Oncology

Volumn 31, Issue 14, 2013, Pages 1726-1731

  Rimawi, Mothaffar F ^a   Mayer, Ingrid A ^b   Forero, Andres ^c   Nanda, Rita ^d   Goetz, Matthew P ^e   Rodriguez, Angel A ^a   Pavlick, Anne C ^a   Wang, Tao ^a   Hilsenbeck, Susan G ^a   Gutierrez, Carolina ^a   Schiff, Rachel ^a   Osborne, C Kent ^a   Chang, Jenny C ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b VANDERBILT INGRAM CANCER CENTER   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d Mayo Clinic College of Medicine   (United States)

^e UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GONADORELIN AGONIST; LAPATINIB; LETROZOLE; TRASTUZUMAB; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; ERBB2 PROTEIN, HUMAN; ESTROGEN RECEPTOR; MONOCLONAL ANTIBODY; NITRILE; QUINAZOLINE DERIVATIVE; TRIAZOLE DERIVATIVE;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANOREXIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER STAGING; CANCER SURGERY; DIARRHEA; DRUG SAFETY; DRUG TOLERABILITY; DRY SKIN; DYSPEPSIA; FATIGUE; FEMALE; GENE OVEREXPRESSION; HEARTBURN; HOT FLUSH; HUMAN; HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 POSITIVE BREAST CANCER; HYPERGLYCEMIA; HYPERTENSION; HYPOCALCEMIA; HYPOKALEMIA; HYPONATREMIA; INSOMNIA; LIVER FUNCTION TEST; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MOLECULARLY TARGETED THERAPY; MOOD DISORDER; MUCOSA INFLAMMATION; MULTICENTER STUDY; NAUSEA; PHASE 2 CLINICAL TRIAL; POSTMENOPAUSE; PREMENOPAUSE; PRIORITY JOURNAL; RASH; SIDE EFFECT; STOMATITIS; TASTE DISORDER; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR BIOPSY; TUMOR VOLUME; ADJUVANT THERAPY; BREAST TUMOR; CHEMISTRY; DRUG ADMINISTRATION; ETHNOLOGY; LYMPH NODE METASTASIS; METHODOLOGY; MIDDLE AGED; PATHOLOGY; TREATMENT OUTCOME; UPREGULATION;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LYMPHATIC METASTASIS; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; NITRILES; QUINAZOLINES; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; TREATMENT OUTCOME; TRIAZOLES; UP-REGULATION;

MLCS; MLOWN;

EID: 84879473563     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.44.8027     Document Type: Article

References (47)

1. Maurer CA, Friess H, Kretschmann B, et al: Increased expression of erbB3 in colorectal cancer is associated with concomitant increase in the level of erbB2. Hum Pathol 29:771-777, 1998
2. Alimandi M, Romano A, Curia MC, et al: Cooperative signaling of ErbB3 and ErbB2 in neoplastic transformation and human mammary carcinomas. Oncogene 10:1813-1821, 1995
3. Wallasch C, Weiss FU, Niederfellner G, et al: Heregulin-dependent regulation of HER2/neu oncogenic signaling by heterodimerization with HER3. EMBO J 14:4267-4275, 1995
4. Agus DB, Akita RW, Fox WD, et al: Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell 2:127-137, 2002
5. Tzahar E, Yarden Y: The ErbB-2/HER2 oncogenic receptor of adenocarcinomas: From orphan-hood to multiple stromal ligands. Biochim Biophys Acta 1377:M25–M37, 1998
6. Yarden Y, Sliwkowski MX: Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2:127-137, 2001
7. Burgess AW, Cho HS, Eigenbrot C, et al: An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors. Mol Cell 12:541-552, 2003
8. Citri A, Yarden Y: EGF-ERBB signalling: Towards the systems level. Nat Rev Mol Cell Biol 7:505-516, 2006
9. Arteaga CL: ErbB-targeted therapeutic approaches in human cancer. Exp Cell Res 284:122-130, 2003
10. Slamon DJ, Leyland-Jones B, Shak S, et al: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783-792, 2001
11. Vogel CL, Cobleigh MA, Tripathy D, et al: Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 20:719-726, 2002
12. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al: Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353:1659-1672, 2005
13. Romond EH, Perez EA, Bryant J, et al: Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353: 1673-1684, 2005
14. Wehrman TS, Raab WJ, Casipit CL, et al: A system for quantifying dynamic protein interactions defines a role for Herceptin in modulating ErbB2 interactions. Proc Natl Acad Sci U S A 103:19063-19068, 2006
15. Junttila TT, Akita RW, Parsons K, et al: Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941. Cancer Cell 15:429-440, 2009
16. Yarden Y: Biology of HER2 and its importance in breast cancer. Oncology 61:1-13, 2001 (suppl 2)
17. Mohsin SK, Weiss HL, Gutierrez MC, et al: Neoadjuvant trastuzumab induces apoptosis in primary breast cancers. J Clin Oncol 23:2460-2468, 2005
18. Nagata Y, Lan KH, Zhou X, et al: PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 6:117-127, 2004
19. Berns K, Horlings HM, Hennessy BT, et al: A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 12:395-402, 2007
20. Diermeier S, Horváth G, Knuechel-Clarke R, et al: Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation. Exp Cell Res 304:604-619, 2005
21. Motoyama AB, Hynes NE, Lane HA: The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides. Cancer Res 62: 3151-3158, 2002
22. Ghosh R, Narasanna A, Wang SE, et al: Trastuzumab has preferential activity against breast cancers driven by HER2 homodimers. Cancer Res 71: 1871-1882, 2011
23. Li J, Yen C, Liaw D, et al: PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 275:1943-1947, 1997
24. Samuels Y, Wang Z, Bardelli A, et al: High frequency of mutations of the PIK3CA gene in human cancers. Science 304:554, 2004
25. Bachman KE, Argani P, Samuels Y, et al: The PIK3CA gene is mutated with high frequency in human breast cancers. Cancer Biol Ther 3:772-775, 2004
26. Scaltriti M, Eichhorn PJ, Cortés J, et al: Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2 breast cancer patients. Proc Natl Acad Sci U S A 108:3761-3766, 2011
27. Mittendorf EA, Liu Y, Tucker SL, et al: A novel interaction between HER2/neu and cyclin E in breast cancer. Oncogene 29:3896-3907, 2010
28. Dave B, Migliaccio I, Gutierrez MC, et al: Loss of phosphatase and tensin homolog or phosphoinositol-3 kinase activation and response to trastuzumab or lapatinib in human epidermal growth factor receptor 2–over-expressing locally advanced breast cancers. J Clin Oncol 29:166-173, 2011
29. Sperinde J, Jin X, Banerjee J, et al: Quantitation of p95HER2 in paraffin sections by using a p95-specific antibody and correlation with outcome in a cohort of trastuzumab-treated breast cancer patients. Clin Cancer Res 16:4226-4235, 2010
30. Arribas J, Baselga J, Pedersen K, et al: P95HER2 and breast cancer. Cancer Res 71:1515-1519, 2011
31. Liu CY, Yang W, Li JF, et al: Effect of trastuzumab on tumor cell lines shedding high or low level of HER-2 ECD [in Chinese]. Zhonghua Zhong Liu Za Zhi 29:101-105, 2007
32. Ritter CA, Perez-Torres M, Rinehart C, et al: Human breast cancer cells selected for resistance to trastuzumab in vivo overexpress epidermal growth factor receptor and ErbB ligands and remain dependent on the ErbB receptor network. Clin Cancer Res 13:4909-4919, 2007
33. Wang YC, Morrison G, Gillihan R, et al: Different mechanisms for resistance to trastuzumab versus lapatinib in HER2-positive breast cancers: Role of estrogen receptor and HER2 reactivation. Breast Cancer Res 13:R121, 2011
34. Nahta R, Yuan LX, Zhang B, et al: Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells. Cancer Res 65:11118-11128, 2005
35. Brand TM, Iida M, Li C, et al: The nuclear epidermal growth factor receptor signaling network and its role in cancer. Discov Med 12:419-432, 2011
36. Franklin MC, Carey KD, Vajdos FF, et al: Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. Cancer Cell 5:317-328, 2004
37. Xia W, Mullin RJ, Keith BR, et al: Anti-tumor activity of GW572016: A dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways. Oncogene 21: 6255-6263, 2002
38. Arpino G, Gutierrez C, Weiss H, et al: Treatment of human epidermal growth factor receptor 2-overexpressing breast cancer xenografts with multiagent HER-targeted therapy. J Natl Cancer Inst 99:694-705, 2007
39. Rimawi MF, Wiechmann LS, Wang YC, et al: Reduced dose and intermittent treatment with lapatinib and trastuzumab for potent blockade of the HER pathway in HER2/neu-overexpressing breast tumor xenografts. Clin Cancer Res 17:1351-1361, 2011
40. Konecny GE, Pegram MD, Venkatesan N, et al: Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res 66:1630-1639, 2006
41. Nahta R, Yuan LX, Du Y, et al: Lapatinib induces apoptosis in trastuzumab-resistant breast cancer cells: Effects on insulin-like growth factor I signaling. Mol Cancer Ther 6:667-674, 2007
42. Scaltriti M, Verma C, Guzman M, et al: Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity. Oncogene 28:803-814, 2009
43. Hanahan D, Weinberg RA: Hallmarks of cancer: The next generation. Cell 144:646-674, 2011
44. Hanahan D, Weinberg RA: The hallmarks of cancer. Cell 100:57-70, 2000
45. Moody SE, Perez D, Pan TC, et al: The transcriptional repressor Snail promotes mammary tumor recurrence. Cancer Cell 8:197-209, 2005
46. Gianni L, Pienkowski T, Im YH, et al: Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): A randomised multicentre, open-label, phase 2 trial. Lancet Oncol 13:25-32, 2012
47. Baselga J, Bradbury I, Eidtmann H, et al: Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): A randomised, open-label, multicentre, phase 3 trial. Lancet 379:633-640, 2012